Objective - To evaluate and compare the long-term efficacy and safety of two different beta-interferon preparations (IFN-beta-1a vs IFN-beta-1b). Material and Methods - Two parallel outpatient groups with relapsing-remitting multiple sclerosis (RRMS), according to Poser criteria, were treated with either intramuscular IFN-beta-1a 30 mu g (group A, n = 62) or subcutaneous IFN-beta-1b 250 mu g (group B, n = 64). Results - A statistically significant reduction was seen in the relapse rate (P < 0.0001) in both groups. No significant difference was found between the two groups (P = 0.43). After 6 years of therapy, the mean Expanded Disability Status Scale score was 3.22 +/- 1.47 (Delta 1.03 +/- 1.35) in group A and 3.34 +/- 1.47 (Delta 0.97 +/- 1.47) in group B (P = 0.47). Conclusion - Our study results suggest that the efficacy of IFN-beta-1a 30 mu g once weekly and SC IFN-beta-1b 250 mu g every other day is similar. Both IFN-beta-1a and IFN-beta-1b are effective in slowing disability progression

Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study

PATTI, Francesco;
2006-01-01

Abstract

Objective - To evaluate and compare the long-term efficacy and safety of two different beta-interferon preparations (IFN-beta-1a vs IFN-beta-1b). Material and Methods - Two parallel outpatient groups with relapsing-remitting multiple sclerosis (RRMS), according to Poser criteria, were treated with either intramuscular IFN-beta-1a 30 mu g (group A, n = 62) or subcutaneous IFN-beta-1b 250 mu g (group B, n = 64). Results - A statistically significant reduction was seen in the relapse rate (P < 0.0001) in both groups. No significant difference was found between the two groups (P = 0.43). After 6 years of therapy, the mean Expanded Disability Status Scale score was 3.22 +/- 1.47 (Delta 1.03 +/- 1.35) in group A and 3.34 +/- 1.47 (Delta 0.97 +/- 1.47) in group B (P = 0.47). Conclusion - Our study results suggest that the efficacy of IFN-beta-1a 30 mu g once weekly and SC IFN-beta-1b 250 mu g every other day is similar. Both IFN-beta-1a and IFN-beta-1b are effective in slowing disability progression
File in questo prodotto:
File Dimensione Formato  
Effect of interferon beta-1a...pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 110.51 kB
Formato Adobe PDF
110.51 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/32113
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 27
social impact